Allergan & Johnson & Johnson Boast Q2 Profits-Yet Cut Jobs: The Sociopathic Business Model™
July 21, 2104
Allergan Q2 profits rise (to an estimated $1.86 billion) yet they cut 1,500 jobs.
Johnson & Johnson Q2 profits rise 14.9% in US Sales yet they cut 400 jobs from Johnson & Johnson’s DePuy Synthes and ending the PurTox development program will result in the elimination of a small number of jobs in the United States, the Johnson & Johnson said.
It would appear that Johnson & Johnson PR is BIG on using SMALL to diminish importance (like in KY when they pulled a small amount of product (in reality pulled millions of units) and again here with a small number of jobs, do we believe them?)
Companies making all this money and employee job loss-well that certainly appears to be Inconsistent & Contradictory language to action and the trigger for The Sociopathic Business Model™ Case Study.
Feel free to send along evidence that supports this theory.